Global Information
회사소개 | 문의 | 위시리스트

축형 척추관절염(axSpA) : 시장 분석과 예측

Axial spondyloarthritis (axSpA) Market and Forecast Analysis to 2037

리서치사 Datamonitor Healthcare
발행일 2018년 07월 상품 코드 527412
페이지 정보 영문 393 Pages
가격
US $ 22,000 ₩ 26,877,000 PDF by E-mail (Single User License)
US $ 107,800 ₩ 131,699,000 PDF by E-mail (Global License)


축형 척추관절염(axSpA) : 시장 분석과 예측 Axial spondyloarthritis (axSpA) Market and Forecast Analysis to 2037
발행일 : 2018년 07월 페이지 정보 : 영문 393 Pages

축형 척추관절염(axSpA) 치료용 출시 약제 및 파이프라인 동향을 조사했으며, 질환 개요, 현재의 치료 옵션, 치료 과제와 미충족 요구, 주요 약제 매출 추이와 예측, 출시 약제 개요, 개발 파이프라인 동향 등의 정보를 정리하여 전해드립니다.

1. axSpA 시장 예측

  • 주요 요약
  • 시장 개요와 시장 동향
  • 시장 정의와 조사 방법
  • Cimzia(certolizumab)
  • Cosentyx(secukinumab)
  • Enbrel(etanercept)
  • Humira(adalimumab)
  • Remicade(infliximab)
  • Simponi(golimumab)
  • Stelara(ustekinumab)
  • Taltz(ixekizumab)
  • 주요 조사 방법

2. axSpA 치료 : 미국, 일본, EU 5개국

  • 주요 요약
  • 주요 조사 방법
  • 질환 정의와 진단
  • 현재의 치료 옵션
  • 처방 동향
  • 컴플라이언스
  • 치료 과제와 미충족 요구
  • 파이프라인 약제의 영향
  • 바이오시밀러의 영향

3. axSpA 역학 : 미국, 일본, EU 5개국

  • 주요 요약
  • 질환의 배경
  • 정보 출처 및 조사 방법
  • 예측 : 강직성 척추염
  • 예측 : 비방사선학적 축형 척추관절염
  • 예측 : 축형 척추관절염
  • 역학자 고찰
  • 강점과 제약

4. 출시 약제

  • 주요 요약
  • 제품 개요
  • KOL(Key Opinion Leader) 조사
  • 제품 개요 : Cimzia
  • 제품 개요 : Cosentyx
  • 제품 개요 : Enbrel
  • 제품 개요 : Humira
  • 제품 개요 : Remicade
  • 제품 개요 : Simponi

5. 파이프라인

  • 주요 요약
  • 임상 파이프라인 개요
  • KOL(Key Opinion Leader) 조사
  • 제품 개요(개발 후기) : Otezla
  • 제품 개요(개발 후기) : Stelara
  • 제품 개요(개발 후기) : Taltz
LSH 17.07.28

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Overview:

Axial spondyloarthritis (axSpA) is a chronic, systemic, inflammatory rheumatic disease that predominantly affects the spine and sacroiliac (SI) joints, leading to chronic back pain. The chronic inflammation can eventually result in new bone formation in the SI joints and spine, causing permanent impairment in spinal mobility. Ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) are the two sub-diseases that comprise axSpA.

Market Snapshot:

  • Uptake of IL inhibitors and US price increases will drive market growth despite downward pressure from biosimilars.
  • Biologic DMARDs are prescribed with increasing frequency as patients move through the axSpA treatment algorithm.
  • Total prevalent cases of axSpA are expected to increase by almost 10% in the US, Japan, and five major EU markets by 2037. Cosentyx has seen strong uptake due to its ability to meet an unmet medical need in TNF-refractory patients.
  • A currently limited pipeline leaves room for developers of novel agents targeting the TNF-refractory population.

TABLE OF CONTENTS

FORECAST: AXIAL SPONDYLOARTHRITIS (Published on 18 May 2018)

  • OVERVIEW
  • RECENT FORECAST UPDATES
  • MARKET DYNAMICS
  • FORECAST AND FUTURE TRENDS
  • MARKET DEFINITION AND METHODOLOGY
  • PRIMARY RESEARCH METHODOLOGY
  • BIBLIOGRAPHY
  • PRODUCT PROFILE: CIMZIA
  • PRODUCT PROFILE: COSENTYX
  • PRODUCT PROFILE: ENBREL
  • PRODUCT PROFILE: HUMIRA
  • PRODUCT PROFILE: REMICADE
  • PRODUCT PROFILE: SIMPONI
  • PRODUCT PROFILE (LATE STAGE): TALTZ

TREATMENT: AXIAL SPONDYLOARTHRITIS (Published on 18 May 2018)

  • OVERVIEW
  • PRIMARY RESEARCH METHODOLOGY
  • DISEASE DEFINITION AND DIAGNOSIS
  • CURRENT TREATMENT OPTIONS
  • PRESCRIBING TRENDS
  • COMPLIANCE
  • TREATMENT CHALLENGES AND UNMET NEEDS
  • IMPACT OF PIPELINE AGENTS
  • IMPACT OF BIOSIMILARS

EPIDEMIOLOGY: AXIAL SPONDYLOARTHRITIS (Published on 17 July 2018)

  • OVERVIEW
  • DISEASE BACKGROUND
  • METHODOLOGY
  • FORECAST
  • BIBLIOGRAPHY
  • APPENDIX: ADDITIONAL SOURCES

MARKETED DRUGS: AXIAL SPONDYLOARTHRITIS (Published on 18 May 2018)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • PRODUCT OVERVIEW
  • PRODUCT PROFILE: CIMZIA
  • PRODUCT PROFILE: COSENTYX
  • PRODUCT PROFILE: ENBREL
  • PRODUCT PROFILE: HUMIRA
  • PRODUCT PROFILE: REMICADE
  • PRODUCT PROFILE: SIMPONI

PIPELINE: AXIAL SPONDYLOARTHRITIS (Published on 18 May 2018)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • CLINICAL PIPELINE OVERVIEW
  • ADDITIONAL PHARMA INTELLIGENCE PIPELINE RESOURCES
  • PRODUCT PROFILE (LATE STAGE): OTEZLA
  • PRODUCT PROFILE (LATE STAGE): TALTZ

LIST OF FIGURES

  • Figure 1: Axial spondyloarthritis - current and future market dynamics analysis
  • Figure 2: Datamonitor Healthcare's assessment summary of key marketed and pipeline drugs for axial spondyloarthritis
  • Figure 3: Total market sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 4: Total axial spondyloarthritis sales across the five major EU markets, by country, 2016-25
  • Figure 5: Total axial spondyloarthritis sales according to drug class, 2016-25
  • Figure 6: Sales of Enbrel and Humira versus other established biologics within axial spondyloarthritis in the US, Japan, and five major EU markets, 2016-25
  • Figure 7: Total axial spondyloarthritis patients across the US, Japan, and five major EU markets, by drug class, 2016-25
  • Figure 8: Total sales of Cosentyx versus Cimzia and Simponi for axial spondyloarthritis in the US, Japan, and five major EU markets, 2016-25
  • Figure 9: Datamonitor Healthcare's axial spondyloarthritis forecast methodology
  • Figure 10: Price sources and calculations, by country
  • Figure 11: Cimzia for axial spondyloarthritis - SWOT analysis
  • Figure 12: Datamonitor Healthcare's drug assessment summary of Cimzia in axial spondyloarthritis
  • Figure 13: Datamonitor Healthcare's drug assessment summary of Cimzia in axial spondyloarthritis
  • Figure 14: Cimzia sales for axial spondyloarthritis across the US and five major EU markets, by country, 2016-25
  • Figure 15: Cosentyx for axial spondyloarthritis - SWOT analysis
  • Figure 16: Datamonitor Healthcare's drug assessment summary of Cosentyx in axial spondyloarthritis
  • Figure 17: Datamonitor Healthcare's drug assessment summary of Cosentyx in axial spondyloarthritis
  • Figure 18: Cosentyx sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 19: Enbrel for axial spondyloarthritis - SWOT analysis
  • Figure 20: Datamonitor Healthcare's drug assessment summary of Enbrel in axial spondyloarthritis
  • Figure 21: Datamonitor Healthcare's drug assessment summary of Enbrel in axial spondyloarthritis
  • Figure 22: Enbrel sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 23: Humira for axial spondyloarthritis - SWOT analysis
  • Figure 24: Datamonitor Healthcare's drug assessment summary of Humira in axial spondyloarthritis
  • Figure 25: Datamonitor Healthcare's drug assessment summary of Humira in axial spondyloarthritis
  • Figure 26: Humira sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 27: Remicade for axial spondyloarthritis - SWOT analysis
  • Figure 28: Datamonitor Healthcare's drug assessment summary of Remicade in axial spondyloarthritis
  • Figure 29: Datamonitor Healthcare's drug assessment summary of Remicade in axial spondyloarthritis
  • Figure 30: Remicade sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 31: Simponi for axial spondyloarthritis - SWOT analysis
  • Figure 32: Datamonitor Healthcare's drug assessment summary of Simponi in axial spondyloarthritis
  • Figure 33: Datamonitor Healthcare's drug assessment summary of Simponi in axial spondyloarthritis
  • Figure 34: Simponi and Simponi Aria sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 35: Taltz for axial spondyloarthritis - SWOT analysis
  • Figure 36: Datamonitor Healthcare's drug assessment summary of Taltz in axial spondyloarthritis
  • Figure 37: Datamonitor Healthcare's drug assessment summary of Taltz in axial spondyloarthritis
  • Figure 38: Taltz sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 39: Proportion of ankylosing spondylitis patients and non-radiographic axial spondyloarthritis patients, by country (%)
  • Figure 40: Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis
  • Figure 41: Diagnosed versus undiagnosed axial spondyloarthritis patients, by country (%)
  • Figure 42: Diagnosed axial spondyloarthritis patients treated by each type of healthcare professional, by country (%)
  • Figure 43: Type of therapy received by diagnosed axial spondyloarthritis patients, by country (%)
  • Figure 44: Treated axial spondyloarthritis patients receiving monotherapy versus combination therapy, by country (%)
  • Figure 45: Distribution of axial spondyloarthritis patients according to monotherapy/combination use, by country (%)
  • Figure 46: Top four regimens used for the treatment of first-line axial spondyloarthritis patients, by country (%)
  • Figure 47: Top four biologic disease-modifying antirheumatic drugs used for the treatment of first-line axial spondyloarthritis patents, by country (%)
  • Figure 48: Total combined biologic disease-modifying antirheumatic drug use for the treatment of axSpA patients at each line of therapy, by country (%)
  • Figure 49: Total combined use of Remicade across all lines of therapy for the treatment of axial spondyloarthritis, by country (%), 2014 and 2016
  • Figure 50: Top four biologic disease-modifying antirheumatic drugs prescribed in Japan for the treatment of axial spondyloarthritis patients after conventional DMARDs, by line of therapy (%)
  • Figure 51: Top five biologic disease-modifying antirheumatic drugs used for the treatment of second-line axial spondyloarthritis patients, by country (%)
  • Figure 52: All prescribed biologic DMARDs used for the treatment of third-line axial spondyloarthritis patients after conventional DMARDs, by country (%)
  • Figure 53: All prescribed biologic DMARDs used for the treatment of fourth-line and later axial spondyloarthritis patients, by country (%)
  • Figure 54: Compliance rate for axial spondyloarthritis treatment, by formulation type and country (%)
  • Figure 55: Top three treatment challenges in axial spondyloarthritis
  • Figure 56: Expected market shares of DMARD-treated axial spondyloarthritis patients for currently approved and pipeline agents five years after launch, by country (%)
  • Figure 57: Physician confidence in prescribing biosimilars for axial spondyloarthritis approved on the basis of indication extrapolation, by country (%)
  • Figure 58: Summary of future usage of biosimilars at one year and three years post-launch (%)
  • Figure 59: Taxonomy of spondyloarthritis
  • Figure 60: ASAS classification criteria for axial spondyloarthritis
  • Figure 61: Trends in total prevalent cases of axial spondyloarthritis in the US, Japan, and five major EU markets, by country, 2017-37
  • Figure 62: Cimzia for axial spondyloarthritis - SWOT analysis
  • Figure 63: Datamonitor Healthcare's drug assessment summary of Cimzia in axial spondyloarthritis
  • Figure 64: Datamonitor Healthcare's drug assessment summary of Cimzia in axial spondyloarthritis
  • Figure 65: Cimzia sales for axial spondyloarthritis across the US and five major EU markets, by country, 2016-25
  • Figure 66: Cosentyx for axial spondyloarthritis - SWOT analysis
  • Figure 67: Datamonitor Healthcare's drug assessment summary of Cosentyx in axial spondyloarthritis
  • Figure 68: Datamonitor Healthcare's drug assessment summary of Cosentyx in axial spondyloarthritis
  • Figure 69: Cosentyx sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 70: Enbrel for axial spondyloarthritis - SWOT analysis
  • Figure 71: Datamonitor Healthcare's drug assessment summary of Enbrel in axial spondyloarthritis
  • Figure 72: Datamonitor Healthcare's drug assessment summary of Enbrel in axial spondyloarthritis
  • Figure 73: Enbrel sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 74: Humira for axial spondyloarthritis - SWOT analysis
  • Figure 75: Datamonitor Healthcare's drug assessment summary of Humira in axial spondyloarthritis
  • Figure 76: Datamonitor Healthcare's drug assessment summary of Humira in axial spondyloarthritis
  • Figure 77: Humira sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 78: Remicade for axial spondyloarthritis - SWOT analysis
  • Figure 79: Datamonitor Healthcare's drug assessment summary of Remicade in axial spondyloarthritis
  • Figure 80: Datamonitor Healthcare's drug assessment summary of Remicade in axial spondyloarthritis
  • Figure 81: Remicade sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 82: Simponi for axial spondyloarthritis - SWOT analysis
  • Figure 83: Datamonitor Healthcare's drug assessment summary of Simponi in axial spondyloarthritis
  • Figure 84: Datamonitor Healthcare's drug assessment summary of Simponi in axial spondyloarthritis
  • Figure 85: Simponi and Simponi Aria sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 86: Taltz for axial spondyloarthritis - SWOT analysis
  • Figure 87: Datamonitor Healthcare's drug assessment summary of Taltz in axial spondyloarthritis
  • Figure 88: Datamonitor Healthcare's drug assessment summary of Taltz in axial spondyloarthritis
  • Figure 89: Taltz sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016-25

LIST OF TABLES

  • Table 1: Total market sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 2: Total axial spondyloarthritis sales according to drug class ($m), 2016-25
  • Table 3: Total axial spondyloarthritis patients across the US, Japan, and five major EU markets, by drug class, 2016-25
  • Table 4: Total sales of cDMARDs methotrexate and sulfasalazine across the US, Japan, and five major EU markets ($m), 2016-25
  • Table 5: Sales of Cosentyx versus Taltz for axial spondyloarthritis in the US, Japan, and five major EU markets ($m), 2016-25
  • Table 6: Exchange rates used for calculating prices
  • Table 7: Rheumatologists surveyed for the axial spondyloarthritis primary research study, 2016
  • Table 8: Cimzia drug profile
  • Table 9: Cimzia pivotal trial data in axial spondyloarthritis
  • Table 10: Cimzia ongoing late-phase trial in axial spondyloarthritis
  • Table 11: Cimzia sales for axial spondyloarthritis across the US and five major EU markets, by country ($m), 2016-25
  • Table 12: Cosentyx drug profile
  • Table 13: Cosentyx pivotal trial data in axial spondyloarthritis
  • Table 14: Late-phase trials for Cosentyx in axial spondyloarthritis
  • Table 15: Ongoing late-phase trials for Cosentyx in axial spondyloarthritis
  • Table 16: Cosentyx sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 17: Enbrel drug profile
  • Table 18: Enbrel pivotal trial data in axial spondyloarthritis
  • Table 19: Enbrel late-phase trial data in axial spondyloarthritis
  • Table 20: Enbrel sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 21: Humira drug profile
  • Table 22: Humira pivotal trial data in axial spondyloarthritis
  • Table 23: Humira late-phase trial data in axial spondyloarthritis
  • Table 24: Humira sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 25: Remicade drug profile
  • Table 26: Remicade pivotal trial data in axial spondyloarthritis
  • Table 27: Remicade sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 28: Simponi drug profile
  • Table 29: Simponi pivotal trial data in axial spondyloarthritis
  • Table 30: Simponi Aria pivotal trial data in axial spondyloarthritis
  • Table 31: Simponi and Simponi Aria sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 32: Taltz drug profile
  • Table 33: Taltz Phase III trials in axial spondyloarthritis
  • Table 34: Taltz sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 35: Rheumatologists surveyed for the axial spondyloarthritis primary research study, March 2016
  • Table 36: Key generic conventional disease-modifying antirheumatic drugs for the treatment of axial spondyloarthritis
  • Table 37: Key marketed biologic disease-modifying antirheumatic drugs for the treatment of axial spondyloarthritis
  • Table 38: Total combined usage of methotrexate and sulfasalazine, as monotherapies and combinations, for treatment of axSpA, by line of therapy and country (%)
  • Table 39: Total combined biologic disease-modifying antirheumatic drug use for the treatment of axSpA patients at each line of therapy, by country (%)
  • Table 40: Current usage of biosimilar infliximab, according to respondents currently prescribing the biosimilar, by country (%)
  • Table 41: Compliance rate for axial spondyloarthritis treatment, by formulation type and country (%)
  • Table 42: Relative importance of treatment challenges in axial spondyloarthritis
  • Table 43: Future usage of biosimilar infliximab, according to respondents aware of biosimilars, by country (%)
  • Table 44: Sources used for the epidemiological analysis of ankylosing spondylitis in the US, Japan, and five major EU markets, by country
  • Table 45: Total prevalent cases of axial spondyloarthritis in the US, Japan, and five major EU markets, by country, 2017-37
  • Table 46: Profiled key marketed drugs for axial spondyloarthritis
  • Table 47: Cimzia drug profile
  • Table 48: Cimzia pivotal trial data in axial spondyloarthritis
  • Table 49: Cimzia ongoing late-phase trial in axial spondyloarthritis
  • Table 50: Cimzia sales for axial spondyloarthritis across the US and five major EU markets, by country ($m), 2016-25
  • Table 51: Cosentyx drug profile
  • Table 52: Cosentyx pivotal trial data in axial spondyloarthritis
  • Table 53: Late-phase trials for Cosentyx in axial spondyloarthritis
  • Table 54: Ongoing late-phase trials for Cosentyx in axial spondyloarthritis
  • Table 55: Cosentyx sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 56: Enbrel drug profile
  • Table 57: Enbrel pivotal trial data in axial spondyloarthritis
  • Table 58: Enbrel late-phase trial data in axial spondyloarthritis
  • Table 59: Enbrel sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 60: Humira drug profile
  • Table 61: Humira pivotal trial data in axial spondyloarthritis
  • Table 62: Humira late-phase trial data in axial spondyloarthritis
  • Table 63: Humira sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 64: Remicade drug profile
  • Table 65: Remicade pivotal trial data in axial spondyloarthritis
  • Table 66: Remicade sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 67: Simponi drug profile
  • Table 68: Simponi pivotal trial data in axial spondyloarthritis
  • Table 69: Simponi Aria pivotal trial data in axial spondyloarthritis
  • Table 70: Simponi and Simponi Aria sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 71: Profiled pipeline products in development for axial spondyloarthritis
  • Table 72: Otezla drug profile
  • Table 73: Otezla Phase III data in axial spondyloarthritis
  • Table 74: Taltz drug profile
  • Table 75: Taltz Phase III trials in axial spondyloarthritis
  • Table 76: Taltz sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016-25
Back to Top
전화 문의
F A Q